Cellectis soars as Pfizer fronts $80m for immuno-oncology
This article was originally published in Scrip
Executive Summary
Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.
You may also be interested in...
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.